Meningitis Research
Meningitis Vaccine Studies - Perth
Meningococcal B Vaccine Study for 12 to 18 months
Vaccine Trials Group is looking for toddlers aged 12 to 18 months to take part in a study to look at an investigational vaccine against Meningococcal B Disease.
Meningococcal B Disease is a severe and rapid-onset infection which can result in death within hours, due to septicaemia (blood poisoning) or meningitis.
There are 5 blood tests involved in this study in Stage 1 plus potentially a further 3 in Stage 2. A numbing cream can be used to minimise discomfort.
There are no costs to you and limited free parking is available at the study centre.
If you would like more information or are interested in participating please contact Vaccine Trials Group by phone on 08 9340 8542 or email menbtoddler@telethonkids.org.au
Study Status: Currently Recruiting until September 2016
Source: Vaccine Trials Group
Article:
The meningococcal Y strain and how it can also cause Pneumonia 2019
Read this article now (946.7 Kb)
Article:
Meningococcal B Study “B Part of it” Professor Helen Marshall 2018
Article:
Lifetime Cost of meningococcal disease in France 2015 – Meningitis Research Foundation
Read this article now (387.3 Kb)
Article:
Costs of surviving meningococcal disease in Spain 2014 – Meningitis Research Foundation
Read this article now (426.2 Kb)
Article:
Counting the Cost of Meningococcal Disease 2013 – Meningitis Research Foundation
Read this article now (384.3 Kb)
Article:
Lancet Medical Journal September 7, 2013
Read this article now on Meningococcal B (141 Kb)
Article:
The changing epidemiology of invasive pneumococcal disease in Aboriginal and Non-Aboriginal Western Australians from 1997 to 2007 and emergence of nonvaccine serotypes
This research article by Principal Research Fellow Deborah Lehmann and colleagues reviewed 10 years of data on invasive pneumococcal disease in Western Australia.
Invasive pneumococcal disease is caused by the bacteria Streptococcus pneumoniae, more commonly known as the pneumococcus.
Meningitis is one form of invasive pneumococcal disease. Since the introduction of the conjugate pneumococcal vaccine (7vPCV) for Aboriginal children in 2001 and later for all other Australian children in 2005, the rates of invasive pneumococcal disease have significantly declined. There has also been a decline in the rates of disease seen in non-Aboriginal adults. However, the current pneumococcal vaccine only covers seven out of more than 90 different types of the pneumococcus bacteria. While there has been a decline in invasive pneumococcal disease caused by these seven types, the rates of invasive pneumococcal disease caused by the other 'non-vaccine' types are now rising.
This article was published in Clinical Infectious Diseases on 1 June 2010.
Read this article now (331 Kb)
Article:
Decline in meningitis admissions in young children: vaccines make a difference
This research article by PhD student Hannah Moore and Principal Research Fellow Deborah Lehmann looked at hospital admissions for children with meningitis all over Western Australia. This analysis of hospital records for children aged under 2 years in Western Australia found admission rates for meningitis dropped by more than 70 per cent between 1992 and 2000. It is thought that the introduction of the Hib (Haemophilus influenzae type b) vaccine to the childhood immunisation schedule in 1993 has caused this dramatic drop in the number of children hospitalised with meningitis.
This article was published in the 2nd October 2006 edition of The Medical Journal of Australia.
